Smyth MJ - Search Results

1

Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.

Blake SJ, Dougall WC, Miles JJ, Teng MW, Smyth MJ. Blake SJ, et al. Among authors: smyth mj. Clin Cancer Res. 2016 Nov 1;22(21):5183-5188. doi: 10.1158/1078-0432.CCR-16-0933. Epub 2016 Sep 12. Clin Cancer Res. 2016. PMID: 27620276 Review.

2

Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.

Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK. Haynes NM, et al. Among authors: smyth mj. Blood. 2002 Nov 1;100(9):3155-63. doi: 10.1182/blood-2002-04-1041. Blood. 2002. PMID: 12384413 Free article.

3

Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.

Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK. Haynes NM, et al. Among authors: smyth mj. J Immunol. 2002 Nov 15;169(10):5780-6. doi: 10.4049/jimmunol.169.10.5780. J Immunol. 2002. PMID: 12421958

4

Nature's TRAIL--on a path to cancer immunotherapy.

Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Smyth MJ, et al. Immunity. 2003 Jan;18(1):1-6. doi: 10.1016/s1074-7613(02)00502-2. Immunity. 2003. PMID: 12530970 Free article. Review.

5

Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells.

Stewart TJ, Smyth MJ, Fernando GJ, Frazer IH, Leggatt GR. Stewart TJ, et al. Among authors: smyth mj. Cancer Res. 2003 Jun 15;63(12):3058-60. Cancer Res. 2003. PMID: 12810627

6

A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.

Moeller M, Haynes NM, Trapani JA, Teng MW, Jackson JT, Tanner JE, Cerutti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK. Moeller M, et al. Among authors: smyth mj. Cancer Gene Ther. 2004 May;11(5):371-9. doi: 10.1038/sj.cgt.7700710. Cancer Gene Ther. 2004. PMID: 15060573

7

Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes.

Teng MW, Kershaw MH, Moeller M, Smyth MJ, Darcy PK. Teng MW, et al. Among authors: smyth mj. Hum Gene Ther. 2004 Jul;15(7):699-708. doi: 10.1089/1043034041361235. Hum Gene Ther. 2004. PMID: 15242530

8

Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer.

Kershaw MH, Jackson JT, Haynes NM, Teng MW, Moeller M, Hayakawa Y, Street SE, Cameron R, Tanner JE, Trapani JA, Smyth MJ, Darcy PK. Kershaw MH, et al. Among authors: smyth mj. J Immunol. 2004 Aug 1;173(3):2143-50. doi: 10.4049/jimmunol.173.3.2143. J Immunol. 2004. PMID: 15265951

9

Cytokines in cancer immunity and immunotherapy.

Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Smyth MJ, et al. Immunol Rev. 2004 Dec;202:275-93. doi: 10.1111/j.0105-2896.2004.00199.x. Immunol Rev. 2004. PMID: 15546400 Review.

10

Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer.

Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y. Smyth MJ, et al. J Exp Med. 2005 Jun 20;201(12):1973-85. doi: 10.1084/jem.20042280. J Exp Med. 2005. PMID: 15967825 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

666 results

Search Page

Filters